相关临床试验
81
4 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
2
2.5%
已完成
45
55.6%
Enrolling By Invitation
1
1.2%
尚未招募
1
1.2%
招募中
2
2.5%
终止
2
2.5%
Unknown
27
33.3%
撤回
1
1.2%
暂无批准数据
- An experimental cancer drug called CADD522, originally developed to block a protein driving tumor growth, strengthened bones and reduced body fat in post-menopausal mice. - Mice treated with CADD522 for eight weeks showed increased bone volume, better preservation of bone microarchitecture, and stimulated new bone growth without suppressing normal bone turnover. - Treated mice weighed less and had fewer fat deposits in bone marrow despite eating the same amount of food, suggesting potential metabolic benefits beyond bone health. - The drug was well tolerated orally in mice, rats and dogs, and metabolized more slowly in human tissue, but remains in early animal testing stages.
- A systematic review and meta-analysis of nine studies covering 480,479 participants found frequent stair climbing was associated with a 39% lower risk of dying from cardiovascular causes. - The same analysis reported a 24% lower risk of all-cause mortality among regular stair climbers compared with those who rarely took the stairs. - A sub-analysis suggested roughly six flights, or 60 to 70 steps per day, marked the point of greatest cardiovascular risk reduction, though researchers said more stairs yielded greater benefit. - Investigators from the University of East Anglia and Norfolk and Norwich University Hospital cautioned that the largely observational, self-reported evidence cannot prove stair climbing itself prevents heart disease.
- The landmark MACRO trial, the most extensive clinical investigation into chronic rhinosinusitis management to date, demonstrated that endoscopic sinus surgery significantly outperformed both clarithromycin antibiotics and placebo in improving quality of life scores at six months. - The study found no significant benefit from three-month clarithromycin treatment compared to placebo, challenging the routine use of long-term macrolide antibiotics in chronic rhinosinusitis patients. - Results support offering sinus surgery earlier in the treatment pathway without delay if symptoms don't respond to intranasal medications, potentially reducing unnecessary antibiotic prescriptions and associated resistance concerns.
- Researchers at the University of East Anglia developed the first blood-based diagnostic test for ME/CFS using epigenetic markers, achieving 96% accuracy with 92% sensitivity and 98% specificity in distinguishing severe patients from healthy controls. - The EpiSwitch® CFS test analyzes 3D chromosomal conformations in blood cells and identified 200 key biomarkers distributed across multiple chromosomes, suggesting ME/CFS involves complex genomic dysregulation rather than single-gene defects. - Pathway analysis revealed the epigenetic signatures strongly correlate with immune dysfunction, particularly IL-2 signaling pathways, and showed overlap with therapeutic targets for rituximab and copaxone, potentially enabling personalized treatment approaches. - The test represents a significant advancement over existing diagnostic approaches that rely solely on clinical criteria, offering hope for earlier diagnosis and better management of the 17-24 million people worldwide affected by this debilitating condition.
- A phase 4 randomized controlled trial involving 514 patients found endoscopic sinus surgery significantly more effective than clarithromycin or placebo for treating chronic rhinosinusitis symptoms. - Surgery patients showed significantly lower SNOT-22 quality-of-life scores at 6 months compared to antibiotic treatment, with 87% reporting improved quality of life. - The three-month course of low-dose clarithromycin showed no significant benefit over placebo, challenging routine long-term antibiotic use in chronic rhinosinusitis management. - Results could streamline clinical pathways and reduce unnecessary antibiotic prescriptions while improving patient access to effective surgical intervention.
- A large meta-analysis of 167 studies across eight vertebrate species found that rapamycin extends lifespan as effectively as dietary restriction and intermittent fasting. - The PEARL clinical trial demonstrated that low-dose rapamycin was safe and well-tolerated in 114 healthy adults aged 50-85, with women showing significant gains in lean muscle mass. - Rapamycin's consistent anti-aging effects across species and sexes strengthen the case for further human longevity research, offering a potential alternative to challenging long-term dietary interventions.
